Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03474887
Other study ID # 2017/948
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 30, 2018
Est. completion date December 20, 2021

Study information

Verified date January 2022
Source Region Skane
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

BACKGROUND/SIGNIFICANCE: With developments in mobile health and the abundance of smartphones, online consultations have emerged as a popular form of primary care in Sweden. Controversy exists regarding diagnostic accuracy, appropriate prescription of antibiotics, and effects on care-seeking patient behavior following implementation of online consultations. As empirical research is lacking, the investigators seek to evaluate online primary care consultations compared to physical consultations with regards to non-inferiority of antibiotic prescription for chief complaint of sore throat. METHODS: Medical record data is used to identify patients with a chief complaint of sore throat, cough/common cold/influenza, or dysuria after choosing online (DIGI) or physical (PHYSI) consultations. A cohort of patients with similar chief complaints prior to implementation of online consultations was used as a control group (CONTROL). Prospective data from local registries and medical records was gathered 14 days the consultation. The primary outcome was rate of antibiotic prescription after sore throat. Secondary outcomes included patient revisits (including hospital admissions), patient satisfaction, time to physician contact, registered diagnosis, and documentation or Centor Criteria and Urinary Tract Infection (UTI)-Criteria. SIGNIFICANCE: Results will shed light on whether antibiotic prescription differs significantly between digital and physical primary care consultations. Hypotheses may also be generated as to how patients seek care in light of improved availability in a tax-sponsored healthcare system.


Description:

Due to limited recruitment of PHYSI and CONTROL patients, these cohorts will be combined into a single physical cohort to provide adequate power for analysis as per predefined required sample size.


Recruitment information / eligibility

Status Completed
Enrollment 4057
Est. completion date December 20, 2021
Est. primary completion date December 6, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient seeking care at primary healthcare provider (Capio in Skåne or Capio Go) - Patient who according to medical record presents with sore throat, cough/common cold/influenza, or dysuria Exclusion Criteria: - Patient who according to medical record presents with main symptom other than sore throat, cough/common cold/influenza, or dysuria. - Patient under the age of 18.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Physical Consultation
Regular physician consultation at the primary care clinic.
Online Consultation
An online platform for communicating with a physician digitally. Patients answer a series of algorithm-based questions after specifying chief complaint, after which contact is established with a physician who can communicate through short messages. The physician can then order labs, prescribe relevant medication or book the patient for a physical consultation if need be.

Locations

Country Name City State
Sweden Capio Go Malmö

Sponsors (5)

Lead Sponsor Collaborator
Region Skane Capio Go, Capio Group, Doctrin, Lund University

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Antibiotics Prescription After Sore Throat Proportion of patients prescribed an antibiotics (as documented in medical records) in conjunction with their initial visit with chief complaint sore throat. 24 hours
Secondary Antibiotics Prescription After Cough/Common Cold/Influenza Proportion of patients prescribed an antibiotics (as documented in medical records) in conjunction with their initial visit with chief complaint cough/common cold/influenza. 24 hours
Secondary Antibiotics Prescription After Dysuria Proportion of patients prescribed an antibiotics (as documented in medical records) in conjunction with their initial visit with chief complaint dysuria. 24 hours
Secondary Patient Revisits Number of healthcare-system visits following initial consultation (as documented in local registries). Includes outpatient as well as inpatient visits. 14 days
Secondary Type of Antibiotic Prescribed ATC-codes of antibiotics prescribed in conjunction with the initial consultation. 24 hours
Secondary Registered Diagnosis Diagnosis registered in with medical journal in conjunction with with initial consultation. 24 hours
Secondary Patient Satisfaction Average scores documented on a 3 question survey, if documented. 24 hours
Secondary Time to Physician Contact DIGI: Time from patient log-in on the online platform to first speech-bubble from the physician.
PHYSI and CONTROL: Time from registered telephone contact to registered physician contact.
14 days
Secondary Centor Criteria Documentation Proportion of patients where Centor Criteria are fully documented in the medical record in conjunction with the initial consultation.
Centor criteria: Tonsillar redness/exudates, Tender anterior cervical adenopathy, fever over 38,5° C, absence of cough.
24 hours
Secondary UTI Criteria Documentation Proportion of patients where urinary tract infection criteria are fully documented in the medical record in conjunction with the initial consultation.
UTI Criteria: increased pain, frequency, urgency. Lack of vaginal symptoms, fever or flank pain.
24 hours
Secondary Ordering of labs for sore throat Defined as "StrepA" quick-test for group A Streptococcus (GAS)-tonsillitis, including outcome 24 hours
Secondary Ordering of labs for dysuria Defined as urinalysis, including outcomes of leukocytes and nitrate 24 hours
See also
  Status Clinical Trial Phase
Completed NCT05523089 - The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Phase 2
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US Phase 3
Completed NCT00968526 - Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00968539 - Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00971425 - Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) Phase 3
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT04695717 - This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam Phase 3
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Completed NCT03888989 - Response to Influenza Vaccine During Pregnancy Phase 1
Completed NCT04109222 - Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively Phase 4
Completed NCT02587221 - Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age Phase 3
Completed NCT03453801 - The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Phase 1
Completed NCT01440387 - A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older Phase 3
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT00972517 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children Phase 3
Completed NCT04570904 - Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
Recruiting NCT03331991 - Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel N/A